Discovery Hub
human T-lymphocyte activation antigen CD80 (activation B7-1 antigen, CTLA-4 counter-receptor B7.1, CD80) extracellular domain containing fragment (1-208 in the current sequence) fused via peptide linker 209GSGGGGSGGGGSGGGGS225 to an Fc fragment of human immunoglobulin G4 (226-454) [Homo sapiens IGHG4*01, hinge ins226>A, S236>P (226-238), CH2 F242>A, L243>A, T258>Q (239-348), CH3 M436>L (349-453), CHS K455>del (454)] fused via peptide/ linker 455GGGGS459 to human interleukin-2 (IL-2, T-cell growth factor (TCGF)) (1-133, 460-592 in the current sequence), variant (R38>A497, F42>A501), dimer (234-234', 237-237')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

human T-lymphocyte activation antigen CD80 (activation B7-1 antigen, CTLA-4 counter-receptor B7.1, CD80) extracellular domain containing fragment (1-208 in the current sequence) fused via peptide linker 209GSGGGGSGGGGSGGGGS225 to an Fc fragment of human immunoglobulin G4 (226-454) [Homo sapiens IGHG4*01, hinge ins226>A, S236>P (226-238), CH2 F242>A, L243>A, T258>Q (239-348), CH3 M436>L (349-453), CHS K455>del (454)] fused via peptide/ linker 455GGGGS459 to human interleukin-2 (IL-2, T-cell growth factor (TCGF)) (1-133, 460-592 in the current sequence), variant (R38>A497, F42>A501), dimer (234-234', 237-237')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

Urothelial Carcinoma

GI Innovation, Inc.protein_peptidePhase 1/2Active

43/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 33/ 100
Competitive Position: 73/ 100

Competitive context

166 Active assets in the Urothelial Carcinoma cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide Beijing Biotech	Phase 3	BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) Vasgene Therapeutics, Inc	Phase 2/3	BB
Pembrolizumab Sutro Biopharma, Inc.	Phase 3	BB
Durvalumab Alliance for Clinical Trials in Oncology	Phase 3	BB
CIS-DIAMMINEDICHLOROPLATINUM II Nagoya University	Phase 3	BB

View all 50 →

Same molecule, other indications

human T-lymphocyte activation antigen CD80 (activation B7-1 antigen, CTLA-4 counter-receptor B7.1, CD80) extracellular domain containing fragment (1-208 in the current sequence) fused via peptide linker 209GSGGGGSGGGGSGGGGS225 to an Fc fragment of human immunoglobulin G4 (226-454) [Homo sapiens IGHG4*01, hinge ins226>A, S236>P (226-238), CH2 F242>A, L243>A, T258>Q (239-348), CH3 M436>L (349-453), CHS K455>del (454)] fused via peptide/ linker 455GGGGS459 to human interleukin-2 (IL-2, T-cell growth factor (TCGF)) (1-133, 460-592 in the current sequence), variant (R38>A497, F42>A501), dimer (234-234', 237-237')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa is also rated in:

nonpapillary renal cell carcinomaDormant

CCC

Indicative ·

48 / 100

View asset →

non-small cell squamous lung carcinomaDormant

CCC

Indicative ·

48 / 100

View asset →

Metastatic Solid TumorDormant

Indicative ·